TSE:TRI

Thomson Reuters Corp (TRI.TO)

147.66
-6.31 (4.10%)
as of Sep 4, 2026, 4:39:32 pm Market Open.
221 watching
0
Investor Insights
star iconSep 4, 2026, 12:00 am

This summary was created by AI, based on 36 opinions in the last 12 months.

Thomson Reuters Corp (TRI) is currently facing significant market skepticism regarding the potential impact of artificial intelligence (AI) on its core legal and financial data services. Despite fears that AI might replace critical aspects of its services, many analysts argue that TRI's extensive proprietary data gives it a strong competitive advantage that will persist in the long term. The company recently showed solid financial performance, including stable topline growth, a significant free cash flow increase, and ongoing share buybacks. While there are concerns about valuation and the market's response to AI developments, sentiments are cautiously optimistic for those willing to view TRI as a long-term investment. Analysts suggest that TRI might be undervalued at its current price, providing an attractive entry point for new investors amidst the prevailing fears.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Fair Value
review icon
Similar
RELX, RELX
PAST TOP PICK
(A past top pick Feb 20/04. No change.) Still likes and feels it is undervalued. 70% of its revenue is the US which has hurt.
DON'T BUY
An exceedingly well run company. Great products. No growth and the stock is expensive.
DON'T BUY
They have a lot of competition in their sector right now which is why the stock has been stuck where it is. Well-run and good assets but think it's overvalued.
BUY
With the stock market going up, this company is attractive.
TOP PICK
Earnings where a little disappointing. Feels they are getting back on track, producing a lot of cash. Sales are a quite strongly. Could have a dividend increase.
DON'T BUY
Their products are not having a particularly good time, and in fact are declining. Have not been able to rally through the stock market rally. A classic under performer and if the market should weaken it will drop more so.
BUY
They do their job very well. 12/15% earnings growth. A very solid, steady stock.
TOP PICK
Was hit hard last year by the strong Cdn$. Has also had slower growth. Last week they had an earnings warning. This has brought it down to a good price. A cash flow rich business.
BUY
Loves this company. Likes their strategy. Expect them to grow 6/7 percent per year.
HOLD
Continuing to hit its quarterly earnings targets.
DON'T BUY
Model price is $32, dead money. Wouldnt touch it, above model price.
TOP PICK
It has got some pretty decent growth and earnings coming through. Good repeat business coming through from the scientific and legal side.
DON'T BUY
The trouble with this company is that they report in US$. Good business and globally diversified but very sensitive to changes in currency.
BUY
Well positioned. Could benefit from a period of market consolidation. It also looks attractive on a technical basis. Safe money.
BUY
We are at the bottom of the economical cycle so expects things will pick up.
Showing 556 to 570 of 718 entries